Drugs / GEN-011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04596033 | Nov 2020 → Jun 2022 | anal squamous cell carcinoma, cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma, melanoma +5 | Genocea Biosciences, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04596033 ↗ |
| Modality | Cell therapy | “GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells.” NCT04596033 ↗ |
| Route | Intravenous | “given back to the patient in one or more intravenous (IV) infusions” NCT04596033 ↗ |